On 13 November 2019, orphan designation EU/3/19/2222 was granted by the European Commission to Real Regulatory Limited, Ireland, for chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4 (also known as NSC-711516 and CAEL-101) for the treatment of AL amyloidosis.
Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4
|Disease / condition||
Treatment of AL amyloidosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.